William Blair Has Strong Forecast for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – William Blair boosted their FY2024 earnings estimates for shares of Dynavax Technologies in a research report issued to clients and investors on Monday, January 13th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.16 for the year, up from their previous forecast of $0.15. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share.

Several other research firms also recently weighed in on DVAX. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright boosted their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.48 on Wednesday. Dynavax Technologies has a one year low of $9.74 and a one year high of $14.41. The business has a fifty day moving average price of $12.76 and a 200-day moving average price of $11.65. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 96.01 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Renaissance Technologies LLC grew its position in shares of Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its holdings in Dynavax Technologies by 87.7% in the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after purchasing an additional 1,109,080 shares in the last quarter. Millennium Management LLC bought a new position in Dynavax Technologies in the 2nd quarter worth approximately $17,615,000. Mizuho Markets Americas LLC grew its holdings in Dynavax Technologies by 17.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock valued at $15,369,000 after buying an additional 204,475 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock valued at $11,848,000 after buying an additional 82,449 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.